BR0208603A - Marcadores de tumor para carcinoma de células renais - Google Patents

Marcadores de tumor para carcinoma de células renais

Info

Publication number
BR0208603A
BR0208603A BR0208603-4A BR0208603A BR0208603A BR 0208603 A BR0208603 A BR 0208603A BR 0208603 A BR0208603 A BR 0208603A BR 0208603 A BR0208603 A BR 0208603A
Authority
BR
Brazil
Prior art keywords
tumor markers
cell carcinoma
renal cell
relates
present
Prior art date
Application number
BR0208603-4A
Other languages
English (en)
Inventor
Roland Kellner
Siegfried Matzku
Barbara Seliger
Rudolf Lichtenfels
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0208603A publication Critical patent/BR0208603A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"MARCADORES DE TUMOR PARA CARCINOMA DE CéLULAS RENAIS". A presente invenção refere-se a marcadores de tumor que podem ser usados para seleção, diagnose e prognóstico e identificação de subtipos de carcinoma de células renais. A presente invenção também refere-se ao uso das proteínas antigênicas identificadas em imunoensaios e ao uso dos marcadores de tumor como imunogênios para estimulação de uma resposta imune. A invenção ainda refere-se ao uso dos marcadores de tumor para a fabricação de anticorpos e proteínas de fusão de anticorpos dirigidas aos marcadores de tumor.
BR0208603-4A 2001-04-03 2002-03-28 Marcadores de tumor para carcinoma de células renais BR0208603A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01108385 2001-04-03
PCT/EP2002/003503 WO2002082076A2 (en) 2001-04-03 2002-03-28 Renal cell carcinoma tumor markers

Publications (1)

Publication Number Publication Date
BR0208603A true BR0208603A (pt) 2004-03-02

Family

ID=8177036

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208603-4A BR0208603A (pt) 2001-04-03 2002-03-28 Marcadores de tumor para carcinoma de células renais

Country Status (15)

Country Link
US (1) US20040096916A1 (pt)
EP (1) EP1373900A2 (pt)
JP (1) JP2004531713A (pt)
KR (1) KR20030086345A (pt)
CN (1) CN1630819A (pt)
BR (1) BR0208603A (pt)
CA (1) CA2442957A1 (pt)
CZ (1) CZ20032787A3 (pt)
HU (1) HUP0303749A3 (pt)
MX (1) MXPA03009018A (pt)
PL (1) PL363009A1 (pt)
RU (1) RU2003130645A (pt)
SK (1) SK12872003A3 (pt)
WO (1) WO2002082076A2 (pt)
ZA (1) ZA200308487B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20040001789A1 (en) * 1999-10-08 2004-01-01 Young David S. F. Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7252821B2 (en) 1999-10-08 2007-08-07 Arius Research Inc. Cancerous disease modifying antibodies
US7670604B2 (en) 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
WO2004055517A2 (en) * 2002-12-13 2004-07-01 Aurelium Biopharma Inc. Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
AU2003300676A1 (en) 2003-01-03 2004-07-29 Aurelium Biopharma Inc. Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7358042B2 (en) 2003-03-14 2008-04-15 Aurelium Biopharma, Inc. Triosephosphate isomerase directed diagnostics and therapeutics for multidrug resistant neoplastic disease
AU2004234399A1 (en) * 2003-04-28 2004-11-11 Wyeth Methods utilising G-protein coupled receptor 54
GB2402212B (en) * 2003-05-28 2007-04-11 Univ Chang Gung Detecting recurrence and high stage bladder carcinoma
PL1720611T3 (pl) * 2004-02-16 2010-09-30 Proteosys Ag Marker diagnostyczny dla raka
CN1712542B (zh) * 2004-06-25 2012-07-04 中国科学院上海生命科学研究院 肝细胞癌相关的蛋白质分子标记原癌蛋白18的筛选及其应用
WO2006066071A2 (en) * 2004-12-17 2006-06-22 Mayo Foundation For Medical Education And Research Prognosis of renal cell carcinoma
US20060148674A1 (en) * 2004-12-31 2006-07-06 Luduena Richard F Therapeutic composition
AU2006210794A1 (en) * 2005-02-01 2006-08-10 Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Biomarkers for tissue status
EP1724585A1 (en) * 2005-05-21 2006-11-22 ProteoSys AG Annexin for cancer risk assessment
EP1724586A3 (en) * 2005-05-21 2007-07-04 ProteoSys AG Annexin for cancer risk assessment
JP2007033041A (ja) * 2005-07-22 2007-02-08 Sumitomo Chemical Co Ltd 胎盤型グルタチオン−ｓ−トランスフェラ−ゼ酵素を認識する抗体に対して陰性を示すラット肝臓腫瘍性病変又は前腫瘍性病変の検定方法
EP1757940A1 (en) 2005-08-26 2007-02-28 Cézanne S.A.S. In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
KR101446626B1 (ko) * 2005-09-02 2014-10-06 도레이 카부시키가이샤 신장암 진단, 신장암 환자 예후 예측을 위한 조성물 및 방법
US20090137063A1 (en) * 2005-11-29 2009-05-28 Karl Skold Method for determining the quality of a biological sample
JP5211315B2 (ja) * 2006-07-25 2013-06-12 国立大学法人愛媛大学 腫瘍マーカ、腫瘍診断キットおよび腫瘍マーカの測定方法
US20090280512A1 (en) 2006-09-15 2009-11-12 Taro Masuda Tumor marker for renal cancer and method for determination of occurrence of renal cancer
AU2008307145B2 (en) * 2007-10-04 2014-07-10 Bionomics Limited Markers of endothelial cells and uses thereof
DE102008011850A1 (de) * 2008-02-29 2009-09-03 Michael Grzendowski Biomarker für die Diagnose von Hirntumor
CN101290321A (zh) * 2008-04-11 2008-10-22 中国医学科学院肿瘤研究所 膜联蛋白a2的血清检测方法、检测试剂盒及其应用
CA2725548A1 (en) * 2008-05-09 2009-11-12 Duke University Autoantibodies in the detection and treatment of cancer
CA2822540A1 (en) * 2011-01-21 2012-07-26 Basilea Pharmaceutica Ag Stathmin as a biomarker for furazanobenzimidazoles
CN102288470A (zh) * 2011-07-20 2011-12-21 中国热带农业科学院热带生物技术研究所 一种考马斯亮蓝g250染色方法及其专用染色液和应用
CN102375061B (zh) * 2011-09-20 2014-07-30 国家人口计生委科学技术研究所 一种检测前列腺癌的elisa试剂盒
JP5872285B2 (ja) * 2011-12-28 2016-03-01 株式会社島津製作所 腎がん血中マーカー
CN104718455B (zh) * 2012-09-07 2017-03-08 基诺麦因有限公司 肾癌血液生物标志物(Biomarker)的检测方法及试剂盒
WO2014066699A1 (en) 2012-10-24 2014-05-01 Tengion, Inc. Renal cell populations and uses thereof
EP2735874A1 (en) * 2012-11-21 2014-05-28 Fundación Para La Investigación Biomédica Del Hospital Universitario Puerta De Hierro Methods of diagnosing and therapeutic agents for use in the treatment of prostate cancer
SE538211C2 (sv) * 2013-04-05 2016-04-05 Idl Biotech Ab Metod för detektering av cytokeratin 8, 18 och/eller 19 och/eller lösliga fragment därav
CN104330570B (zh) * 2014-10-11 2016-03-16 中国科学院微生物研究所 人热休克蛋白gp96在制备筛查肝病的产品中的应用
CN116688096A (zh) 2016-02-04 2023-09-05 免疫系统密钥有限公司 在癌症疗法作为预测工具的内质网应激和用于癌症治疗的联合疗法
CN106526185B (zh) * 2016-10-28 2018-03-30 拜尔康(天津)医药科技有限公司 用于检测去势抵抗性前列腺癌的elisa试剂盒及检测方法
SG10202108135VA (en) * 2016-12-16 2021-09-29 Merck Patent Gmbh Methods for the use of galectin 3 binding protein detected in the urine for monitoring the severity and progression of lupus nephritis
CN113447656B (zh) * 2021-07-01 2022-05-13 浙江大学 检测抗丝状肌动蛋白成帽蛋白β-IgG抗体的试剂盒
CN114099639B (zh) * 2021-11-25 2024-03-01 徐州医科大学 H1-pHSP65纳米疫苗及其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972626A (en) * 1997-07-30 1999-10-26 University Of Massachusetts Cancer detection by centrosome abnormality

Also Published As

Publication number Publication date
HUP0303749A3 (en) 2005-09-28
RU2003130645A (ru) 2005-04-10
CZ20032787A3 (en) 2004-03-17
ZA200308487B (en) 2005-01-31
JP2004531713A (ja) 2004-10-14
KR20030086345A (ko) 2003-11-07
CN1630819A (zh) 2005-06-22
PL363009A1 (en) 2004-11-15
SK12872003A3 (sk) 2004-02-03
CA2442957A1 (en) 2002-10-17
WO2002082076A3 (en) 2003-09-04
MXPA03009018A (es) 2004-02-12
US20040096916A1 (en) 2004-05-20
HUP0303749A2 (hu) 2004-03-01
WO2002082076A2 (en) 2002-10-17
EP1373900A2 (en) 2004-01-02

Similar Documents

Publication Publication Date Title
BR0208603A (pt) Marcadores de tumor para carcinoma de células renais
ES2093778T3 (es) Nuevos anticuerpos y metodos para su uso.
CY1108450T1 (el) Μεθοδος για την ανιχνευση ν-τελικου προβνρ
TR200002284T2 (tr) Mage ailesinden tümör ile ilgili tümör türevleri
DE3382283D1 (de) Monoklonale antikoerper spezifisch gegen das karzinoembryonische antigen.
DE60122286D1 (de) Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
DE69735294D1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
DE3783277T2 (de) Monoklonaler antikoerper gegen humanes lungenkarzinom.
ES2138102T3 (es) Procedimiento para la deteccion de antigeno urinario asociado a tumores.
ATE430939T1 (de) Schwangerschaftsnachweisverfahren
ATE473279T1 (de) In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
DE3586216T2 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
DK0991945T3 (da) Fremgangsmåde til identifikation af tumor-antigener med antistoffer i serum
DK314586A (da) Monoklonale antistoffer og antigener for humane lungecarcinomer, der ikke er af typen med smaa celler
DE69030494D1 (de) Karzinomverwandtes haptoglobin (hpr)
KR830003898A (ko) 인체 암 핵인 항원에 대한 항체를 사용한 인체 암세포의 검출
DE60036692D1 (de) Zusammensetzungen und methoden zur detektion einer trypanosoma cruzi infektion
DE60014064D1 (de) Einetenascin-c isoform als marker für neoplasmen
DK218886A (da) Tvaerreaktive og beskyttende epitoper af circumsporozoit-proteiner
DK0495910T3 (da) Fremstilling og anvendelse af humant nm23-H2-protein og derimod rettede antistoffer
BRPI0409321A (pt) antìgeno hìbrido, competição e método para induzir uma resposta imune para um agente infeccioso ou antìgeno de tumor, método para tratar uma doença infecciosa ou cáncer, e, peptìdeo
SE0100595D0 (sv) Immunological detection of prostate diseases and prostatic-related diseases
NZ333075A (en) isolated protein markers for use in diagnosing esophageal cancer
DE69111429D1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]